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ABSTRACT 
Since, we previously demonstrated that sequentially extracted methanolic fraction showed 
marked antioxidant and antidiabetic property in vitro, the present study was design to evaluate 
the beneficial effects of Phyllanthus virgatus methanolic extract and its partially purified frac-
tion on hyperglycemia and hyperlipidemia in streptozotocin (STZ) induced diabetic rats. The 
plant extract was subjected to repeated thin layer chromatographic fractionation followed by 
GC-MS analysis of active fraction. TLC data illustrated the presence of six prominent bands 
and the prelimnary screening of these bands against α-amylase inhibitory activity showed that 
the band with Rf value 0.514 has marked inhibitory property (IC50, 48 µg/ml). The diabetic 
rats were treated for four weeks with methanolic extract of P. virgatus (50 and 10 
mg/rat/day), partially isolated active fraction (0.5 and 0.1 mg/rat/day) and glibenclamide (0.1 
mg/rat/day). The level of fasting blood glucose (FBG), hemoglobin, glycated hemoglobin 
(HbA1c) and insulin were significantly alleviated in plant extract and partially purified frac-
tion treated group after 28 days of administration. Moreover, total cholesterol (TC), triglycer-
ides (TG), low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-
cholesterol (VLDL-C) and high density lipoprotein cholesterol (HDL-C) were also markedly 
ameliorated in the entire treatment group, with a maximum restoration observed in group 
treated with partially purified fraction (0.5 mg/rat/day). The results demonstrate a strong anti-
diabetic and hypolipidemic impact of plant extract and its partially purified fraction coupled 
with their potent antioxidative property, which can provide additional benefits in the inhibi-
tion of oxidative stress and hence in the prevention and treatment of diabetes as well as diabe-
tes linked hyperlipidemia. 
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INTRODUCTION 
Diabetes mellitus is reaching as epidemic 
proportion across the globe, a metabolic dis-
order characterize by hyperglycemia result-
ing from defect in insulin secretion, insulin 
action or both (ADA, 2009). Currently, there 
are 40 million people with diabetes in India 
estimated to rise to almost 70 million by 
2025 (IDF, 2006). Hyperglycemia is the 
most important factor in the onset and pro-
gress of diabetic complications mainly by 
producing oxidative stress (Giugliano et al., 
1996). Altered cellular metabolism caused 
by hyperglycemia has been suggested to play 
an important role in increasing the risk of 
cardiovascular, renal, ophthalmic and neuro-
logical complications of diabetes mellitus 
(Brownlee and Cerami, 1981). The pancreat-
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ic β cells posse the ability to respond to the 
minor change in the plasma glucose level 
and maintain the homeostasis of glucose lev-
el (Hellestrom, 1977). The continuous de-
struction of β-cell leads to the disturbance in 
glucose homeostasis. Liver and pancreas are 
the two main organs which plays important 
role in maintain the level by regulating alter-
native pathways between glucose uptake and 
gluconeogenesis (Ferre et al., 1996).  
The excessive non enzymatic glycosyla-
tion of proteins including low density lipo-
protein (LDL), associated with substantially 
increased superoxide, hydrogen peroxide, 
and hydroxyl radical production, stimulate 
formation of advanced glycosylation end 
products and foam cells, which cause exten-
sive cellular and tissue damage including 
vascular injury (Lyons, 1991). Since, most 
animal studies of diabetes are induced by 
administration of streptozotocin (STZ) or 
alloxan, toxic agents that target -cells, they 
are thus essentially considered as models of 
type 1 diabetes at higher doses or type 2 dia-
betes at lower doses. Nevertheless, such an-
imals show increased lipid peroxidation, hy-
perlipidemia and other diabetic complica-
tions seen in diabetes (Kaji et al., 1985). Li-
pids play a major role in maintaining the in-
tegrity of the biomembrane and maintain its 
structure and function. Due to insulin defi-
ciency, alteration in lipid and lipoprotein as-
sociate diabetes with the higher chance of 
development of pathogenesis atherosclerosis. 
The dyslipidemic profile of diabetics in-
cludes increased levels of triglyceride (TG), 
total cholesterol (TC), very low density lipo-
protein (VLDL-C) and low density lipopro-
tein (LDL-C), increased small dense (sd-
LDL), glycation of LDL and decreased 
plasma high density lipoprotein (HDL) con-
centration (Grundy et al., 1999). Study indi-
cates that altered plasma lipoprotein profile 
in the excess atherosclerosis associated with 
diabetes may be most critical, because at any 
TC level, diabetics have 3-to 5-fold higher 
coronary artery disease (CAD) mortality 
rates than do non diabetic subjects (Steiner, 
2001).  
It has been found that in the developing 
countries where the resources are meager, 
the best source for the management of diabe-
tes mellitus is green medicine (Bnouham et 
al., 2006). It has been attributed that there 
antihyperglycemic potential is due to their 
restoring power of β-cell, smoothing glucose 
fluctuation, increase insulin production and 
competing with the enzymes to manipulate 
carbohydrate metabolism (Elder, 2004). Nat-
ural products, such as plants extract, either as 
pure compounds or as standardized extracts, 
provide unlimited opportunities for new drug 
discoveries because of the unmatched avail-
ability of chemical diversity. We previously 
published that Phyllanthus virgatus Forst 
(Eurphobacea) commonly known as Bhu-
iamla, has great potential as an antioxidant 
and antihyperglycemic agent in vitro 
(Hashim et al., 2013). Phyllanthus has been 
used in Ayurvedic medicine for over 2,000 
years and has a wide number of traditional 
uses. This family includes several plant spe-
cies among all the species; P. amarus, 
P.urinaria, P. maderaspatensis and P. 
fraternus are the most popular ones due to 
their antioxidant properties as well as their 
extensive use in the treatment of disease re-
lated to kidney, liver, urinary bladder, intes-
tinal infection, cancer, and diabetes (Kirtikar 
and Basu, 1933; Girach et al., 2007). P. vir-
gatus is also known traditionally for its re-
medial properties and extensively known for 
antioxidant property and used in the treat-
ment of intestinal, liver, kidney and bladder 
problem (Hashim et al., 2013; Shabeer et al., 
2009; Kirtikar and Basu, 1933; Calixto et al., 
1998; Kumaran and Joel Karunakaran, 
2007). P. virgatus is also rich in tannins, fla-
vonal sulfonates, norlignan compounds 
(Huang et al., 1998), lignans (Huang et al., 
1996), hypophyllanthin, isointetralin, nira-
thin, nirtetralin, phyltetraline, virgatusui, lac-
tone and acids like indole-3-carboxylic acid 
(Calixto et al., 1998), 2,4,5- trimethoxy pro-
penylbenzene, 11-octadecenoic acid, 9,12-
octadecadienoic acid, hexadecanoic acid, 
benzenedicarboxylic acid, tridecyl ester and 
6-octadecynoic acid (Hashim et al., 2013). 
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Based on our previously published data, 
which delineated the in vitro antioxidant, 
genoprotective and α-amylase inhibitory 
property of methanolic extract of P. virgatus, 
the current study was intended to investigate 
hypoglycemic and hypolipidemic property of 
P. virgtaus methanolic extract and its partial-
ly isolated fraction in STZ induced diabetic-
hyperlipidmic rats.  
 
MATERIAL AND METHOD 
Solvent and chemicals 
Streptozotocin (STZ) was procured from 
Himedia Laboratories, Mumbai, India. Por-
cine pancreatic -amylase was procured 
from SRL Pvt. Ltd., Mumbai, India. Mercko-
test glucose oxidase peroxidase (GOD/POD) 
kit, insulin kit, TC, TG kits were obtained 
from Merck, India. Acarbose was procured 
from Bayer Pharmaceuticals and glibencla-
mide was obtained from Sun Pharmaceuti-
cals. All other chemicals and solvents were 
of analytical grade. 
 
Plant material and extraction procedure  
P. virgatus Forst whole plant was col-
lected from the local area around Integral 
University, Lucknow, India, in the months of 
July-August. The plant was botanically iden-
tified and authenticated by Dr. Mohd. Tariq, 
of National Botanical Research Institute 
(NBRI), Lucknow, India and a voucher spec-
imen (98195) of the plant was submitted at 
NBRI. In order to obtain methanolic fraction, 
sequential extraction of P. virgatus whole 
plant was done according to the method of 
(Hashim et al., 2013).  
 
Isolation of bioactive fraction from P. vir-
gatus methanolic extract 
The plant extract was subjected to thin 
layer chromatography (TLC) in order to sep-
arate the bioactive compounds according to 
the procedure of Harborne (1988). Using a 
microcapillary tube, a small drop of meth-
anolic extract of the plant extract was placed 
on the TLC plate, 3 cm above the bottom. 
The chromatogram was developed with chlo-
roform: methanol (9:1) and sprayed with 
10 % H2SO4 and heated at 120 °C for the de-
tection of organic components. The Rf values 
of the spots were calculated by the formula 
 
In view to isolate the bioactive fraction, 
repetitive preparatory TLC was prepared as 
described above. The bands were eluted sep-
arately with methanol and filtered free of sil-
ica gel, dried (Gayatri et al., 2011) and tested 
for α-amylase inhibitory property. 
 
α -amylase inhibition assay  
To determine the in vitro α-amylase inhi-
bition by various TLC fraction of P. vir-
gatus, the procedure of Bernfeld (1955) was 
adopted with slight modification (Hashim et 
al., 2013). Acarbose was used as standard 
inhibitor. 
Inhibition rates were calculated as per-
centage controls using the formula:  
% Inhibition=100 - % reaction 
(where % reaction = mean product in sam-
ple/mean product in control x 100) 
Further, IC50 value represented the con-
centration of the extract that caused 50 % in-
hibition of α-amylase and was calculated by 
interpolation of linear regression analysis. 
 
Gas chromatography and mass spectrosco-
py (GC-MS) analysis 
In order to know the bioactive metabo-
lites responsible for antioxidant, antidiabetic 
and antihyperlipidemic activity, the partially 
isolated fraction of P. virgatus methanolic 
extract was subjected to GC-MS analysis. 
The sample was injected into a RTX-5 col-
umn (60 m x 0.25 mm i.d., film thickness 
0.25 µm) of GC-MS (model GC-MS-QP-
2010 plus, Shimadzu Make). Helium was 
used as carrier gas at a constant column flow 
1.2 ml/min at 173 kpa inlet pressure. Tem-
perature programming was maintained from 
100 °C to 200 °C with constant rise of 
5 °C/min and then held isothermal at 200 °C 
for 6 min; further the temperature was in-
creased by 10 °C/min up to 290 °C and again 
held isothermal at 290 °C for 10 min. The in-
jector and ion source temperatures were 
Distance travelled by the sample 
Distance travelled by the solvent 
Rf =  
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270 °C and 250 °C, respectively. Mass spec-
tra were taken at 70 eV; a scan interval of 0.5 
s and fragments from 40 to 950 Dalton. The 
final confirmation of constituents was made 
by computer matching of the mass spectra of 
peaks with the National Institute of Stand-
ards and Technology (NIST) libraries mass 
spectral database. 
 
Dose preparation 
Sequentially extracted P. virgatus meth-
anolic extract and its partially purified frac-
tion with different concentrations were dis-
solved in 5 % dimethyl sulfoxide and ho-
mogenized with saline. The doses of extract 
were selected on the basis of previously pub-
lished reports (Shabeer et al., 2009). The ref-
erence drug glibenclamide was suspended in 
distilled water for oral administration. The 
animals in control group received buffer on-
ly. 
 
Animals 
Male wistar rats weighing between 180-
220 g were procured from the Indian Insti-
tute of Toxicology Research Center, Luck-
now. This study has been dully approved by 
Institutional animal ethics committee (IAEC) 
vide registration number: IU/Biotech/project/ 
CPCSEA/13/14. The animals were fed on 
normal standard pellet diet with water ad 
libitum, and acclimatized to the laboratory 
conditions for a week. Prior to experimental 
treatment, animals were fasted an overnight, 
but were allowed free access to water. 
 
Induction of diabetes mellitus 
In order to induce experimental diabetes, 
thirty overnight fasted rats were injected 
with STZ, freshly dissolved in 10 mM citrate 
buffer, pH 4.5, 60 mg/kg body weight) intra-
peritonially (Zhang et al., 2004). Rats in 
normal control group were injected with 
buffer only. The fasting blood glucose 
(FBG) level was determined after 48 h of 
STZ injection. The rats depicting FBG ≥ 230 
mg/dl were considered to be diabetic for in-
vestigating the hypoglycemic and hypoli-
pidemic impacts and were divided randomly 
and equally (5 rats in each group) in groups 
as illustrated in Table 1. Plant extract, its iso-
lated fraction and glibenclamide suspension 
was administered through gastric intubation 
in two divided doses (morning and evening) 
of 0.5 ml each/rat/day for 28 days. 
 
Analytical procedures 
Collection of blood and packed erythrocytes  
At the end of the treatment, overnight 
fasted rats in each group were anaesthetized 
and blood was drawn by cardiac puncture. 
The blood from each rat in a given group 
was collected using heparin as anticoagulant. 
Blood was mixed gently by inversion 2-3 
times and immediately cooled to 4 °C in a 
refrigerator. The samples were centrifuged at 
2,500 rpm for 30 min. Plasma was aliquoted 
and either stored at 4 °C or frozen at -20 °C 
for future use.  
Determination of blood glucose 
Fasting plasma glucose levels were de-
termined by using GOD-POD kit by Merck, 
India. The method uses a modified Trinder 
color reaction (Trinder, 1969; Tietz, 1976). 
The color thus formed was measured at 505 
nm in Eppendorf spectrophotometer, which 
is directly proportional to the concentration 
of glucose in the sample. The plasma glucose 
level was calculated by using a standard glu-
cose.  
 
Table 1: Protocol for the treatment of STZ in-
duced diabetic rats 
NC Normal control  
NC+PE Normal control + Plant extract treated (40 mg/rat/day)  
DC Diabetic control  
CT-1 Diabetic + partially purified com-pound (0.5 mg/rat/day)  
CT-2 Diabetic + partially purified com-pound (0.1 mg/rat/day)  
PET-1 Diabetic + plant extract  (50 mg/rat/day)  
PET-2 Diabetic+ plant extract  (10 mg/rat/day)  
D-GT Diabetic + Glibenclamide  (0.1 mg/rat/day)  
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Determination of glycosylated hemoglobin 
The quantitative determination of glyco-
sylated hemoglobin (HbA1c) in erythrocytes 
hemolysate was done by the colorimetric 
method of Nayak and Pattabiraman (1981). 
Fructose was used as standard.  
Determination of plasma insulin  
Plasma insulin level was measured using 
solid phase-conjugated sandwich rat ELISA 
kit Merck Millipore, USA (Pitchai et al., 
2009). 
Determination of plasma triglycerides  
Triglycerides in plasma samples were de-
termined by using glycerol-3-phosphate oxi-
dase-peroxides (GPO-POD) kit from Merck, 
India. The method uses a modified Trinder 
color reaction to produce a fast, linear, end 
point reaction (Trinder, 1969). The intensity 
of the color produced is directly proportional 
to the concentration of triglycerides in the 
sample when measured at 505 nm and results 
were expressed as mg/dl.  
Plasma very-low-density lipoprotein 
(VLDL-C) was determined by dividing 
plasma triglyceride values (mg/dl) by a fac-
tor of 5 as described by Friedewald et al. 
(1972). 
Fractionation of plasma LDL and HDL 
Plasma LDL was isolated by precipita-
tion method as described by Wieland and 
Seidel (1983). The precipitation buffer con-
sisted of 64 mM trisodium citrate adjusted to 
pH 5.05 with 5 N HCl, containing 50,000 
IU/L heparin. Before precipitation of LDL, 
plasma samples and precipitation reagent 
were allowed to equilibrate to room tempera-
ture. One ml of plasma sample was added to 
7.0 ml of heparin-citrate buffer. After mixing 
with a vortex mixer, the suspension was al-
lowed to stand for 10 min at 22 °C. The in-
soluble LDLs were then sedimented by cen-
trifugation at 1,500 rpm for 10 min at 22 °C. 
The pellet was resuspended in 1.0 ml of 0.1 
M sodium phosphate buffer, pH 7.4, contain-
ing 0.9 % NaCl. Isolation of HDL was done 
by the method of Patsch et al. (1989). Ac-
cording to this method 100 µl of reagent con-
taining 1.0 g of dextran sulfate dissolved in 
100.0 ml of 0.5 mM MgCl2 solution was 
added to 1.0 ml of plasma, and vortexed-
mixed for 3 sec. After an incubation period 
of 10 min at 22 °C, the mixture was centri-
fuged at 1500 rpm for 15 min at 22 °C and 
the supernatant containing HDL was re-
moved. The clear supernatant was used for 
the analysis of HDL-Cs. 
Determination of plasma cholesterol 
Total cholesterol in plasma, LDL and 
HDL was determined by using cholesterol 
oxidase phenol aminophenazone (CHOD-
PAP) kit, from Merck India. The intensity of 
the color produced is directly proportional to 
the concentration of cholesterol in the sam-
ple when measured at 505 nm and results 
were expressed as mg/dl.  
 
Statistical analysis  
The data was put across the mean ± SD. 
For statistical analysis of the data, group 
means were compared by one way analysis 
of variance (ANOVA) followed by Dun-
nett´s ´t´test which are used to identify the 
difference between groups. Statistical signif-
icance was expressed as *P < 0.05, 
**P < 0.01 and ***P < 0.001. 
 
RESULTS  
Identification, isolation and α-amylase  
inhibitory property of bioactive fraction 
Our previously published data illustrated 
that among the sequentially extracted frac-
tions of P. virgatus, methanolic extract ex-
hibited significant and most potent antioxi-
dant, genoprotective and antidiabetic proper-
ty in vitro (Hashim et al., 2013). Therefore, 
in the present investigation we aim to isolate 
and identify the bioactive compound present 
in this methanolic extract and also evaluate 
the in vitro and in vivo antidiabetic property. 
In this context, partial purification and isola-
tion was performed by repetitive preparatory 
TLC. The results presented in Figure 1 de-
picted the presence of six prominent bands 
(1-6) with Rf value of 0.16, 0.28, 0.42, 0.541, 
0.71 and 0.76. The bands were scrapped out, 
eluted and initial screening of various bands 
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for in vitro α-amylase inhibitory property 
showed that the 1st, 4th and 6th band with Rf 
value of 0.76, 0.514 and 0.16 depicted sig-
nificant inhibition 29.2 %, 62.11 % and 
17.29 % respectively at 100 µg/ml respec-
tively, while no significant inhibition was 
observed in other bands. Moreover, the 4th 
band (Rf 0.514) illustrated a significant IC50 
value of 47.5 ± 0.56 µg/ml, which was better 
than the standard drug acarbose 
(76.88 ± 0.277 µg/ml) (Table 2). The above 
results confirmed that this band has most po-
tent α- amylase inhibitory property and was 
subjected to GC-MS analysis for the identifi-
cation of bioactive compound. Preliminary 
GC-MS analysis, based on retention tine and 
molecular mass was performed to determine 
the nature of phytoconstituents present in 
partially purified band. The GC-MS spectral 
results and comparison of results with library 
search successfully enable the identification 
of four compounds as illustrated in Figure 2. 
The results revealed that hexadecanoic acid 
(51.11 %) and octadecanoic acid (26.64 %) 
were found to be the two major components 
in the partially isolated band, whereas 9-
Octadecenoic acid (14.39 %) and benzoic ac-
id (7.877 %) were found in less amounts 
(Table 3). The methanolic extract and bioac-
tive fraction was further subjected to in vivo 
study. 
 
 
 
Figure 1: TLC profile of P. virgatus methanolic 
extract  
 
 
 
Table 2: Percentage of α-amylase inhibitory activity of various fractions of P. virgatus isolated via TLC 
TLC Bands/Rf 25 µg/ml 50 µg/ml 100 µg/ml IC50 µg/ml 
Band 1/0.16 12.35% 25.84% 29.28% > 100 
Band 2/0.514 19.4% 54.02% 62.11% 47.45 ± 0.56 
Band 3/0.76 2.44% 8.53% 17.29% > 100 
Acarbose  33.09% 40.07% 59.1% 76.88 ± 0.277 
 
 
Table 3: Bioactive compounds identified via GC/MS analysis from the TLC fraction of P. virgatus 
methanolic extract 
Peak Time retention Area % Identified compound 
1 17.788 7.87 benzoic acid 
2 18.386 51.11 hexadecanoic acid 
3 21.142 14.39 9-octadecenoic acid 
4 21.526 26.64 octadecanoic acid 
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Figure 2: GC-MS analysis of isolated TLC band 
of P. virgatus methanolic extract 
 
 
Impact of P. virgatus methanolic extract, its 
partially isolated fraction and glibenclami-
de on body weight, plasma glucose, insulin, 
blood hemoglobin and glycated hemoglobin 
in diabetic rats treated for 28 days 
Results presented in Figure 3 indicate the 
average body weight of diabetic rats after 28 
days, of treatment with plant extract, its par-
tially purified fraction and glibenclamide. 
After 28 days the body weight of diabetic 
rats was progressively decreased (41.5 %), as 
compared to normal control group. On the 
other hand, oral administration of different 
doses of P. virgatus methanolic extract and 
its partially purified fraction showed signifi-
cant gain in body weight of diabetic rats 
when compared to DC rats, with a maximum 
increase of 34 % in glibenclamide treated 
rats followed by CT-1 (20 %) group. 
At end of experiment (28 days) plasma 
glucose level in DC group was further in-
creased from initial value of 119 mg/dl to 
277 mg/dl (Figure 4). In the entire treated 
group, plant extracts and its partially purified 
compound mediated a significant decrease of 
52 %, 41 %, 42 % and 30 % respectively, in 
plasma glucose level of rats in CT-1, CT-2, 
PET-1 and PET-2 groups. However, a highly 
significant decrease in glucose level was ob-
served in diabetic rats treated with partially 
purified compound which was almost com-
parable to the value obtained in glibencla-
mide treated diabetic rats. 
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Figure 3: Impact of P. virgatus methanolic ex-
tract, its partially purified fraction and gliben-
clamide on the body weight of diabetic rats after 
28 days of treatment.  
Data are expressed in mean ± SD from 4 rats in each group 
except in NC and NC+PE that include 5 rats. * a P < 0.001 
significantly different when compared with the corresponding 
value for normal control rats. *** b P < 0.001 significantly dif-
ferent when compared with the corresponding value for dia-
betic control. NC, normal control; NC-PE, normal control fed 
50 mg plant extract/rat/day; DC, diabetic control; CT-1, fed 
0.5 mg partially isolated fraction of P. virgatus/rat/day; CT-2, 
fed 0.1 mg partially isolated fraction of P. virgatus/rat/day; 
PET-1, fed 50 mg methanolic extract of P. virgatus/rat/day; 
PET-2, fed 10 mg methanolic extract of P. virgatus/rat/day 
and D-GT, given 0.1 mg glibenclamide/rat/day for 28 days 
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Figure 4: Effect of P. virgatus methanolic ex-
tract, its partially purified fraction and gliben-
clamide on plasma glucose level in diabetic rats 
after 28 days of treatment. 
Data are expressed in mean ± SD from 4 rats in each group 
except in NC and NC+PE that includes 5 rats. **a P < 0.01 
significantly different when compared with the corresponding 
value for normal control rats. ***b P < 0.001, significantly dif-
ferent when compared with the corresponding value for dia-
betic control 
 
As expected, after 28 days, Hb level in 
DC rats was significantly reduced (38 %) in 
comparison to rats in NC group. However, a 
highly significant increase in Hb concentra-
tion was observed in diabetic rats treated 
with partially purified compound, CT-1 
(54 %) and CT-2 (51 %), whereas the meth-
anolic extract treated rats also observed a 
marked increase in Hb concentration, when 
compared to DC rats (Table 4). Both partial-
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ly purified fraction (CT-1) and gliben-
clamide (D-GT) administration to diabetic 
rats mediated an increase in Hb level closed 
to normal control value. 
The level of HbA1c which is an index for 
mean blood glucose level for the previous 2-
3 months, was significantly increased by 
207 % in DC rats when compared to a value 
of 4.25 mg/dl of NC rats. After 28 days of 
treatment the mean HbA1c level was signifi-
cantly decreased by 66 %, 48 %, 66 % and 
42 % in CT-1, CT-2, PET-1 and PET-2 
groups, respectively, when compared to val-
ues of DC rats. Our results also illustrated 
that plasma insulin level in DC rats was sig-
nificantly reduced to 51 % in comparison to 
NC rats. On repeated admistration of P. vir-
gatus methanolic extract and its partially iso-
lated fraction a marked increase in insulin 
level of CT-1 (76 %), CT-2 (46 %), PET-1 
(67 %) and PET-2 (83 %) group was ob-
served when compared to DC group (Table 
4). These results demonstrated that among 
all the treated groups, partially purified frac-
tion CT-1 and CT-2 at a dose of 0.5 
mg/rat/day and 0.1 mg/rat/day act as a potent 
hypoglycemic agent in diabetic rats. 
 
Effect of P. virgatus methanolic extract, its 
partially purified fraction and glibenclami-
de on plasma lipid and lipoprotein levels in 
diabetic-hyperlipidemic rats treated for 28 
days  
The induction of experimental diabetes in 
rats by STZ had a reflective impact on lipid 
parameter when compared to normal rats. As 
shown in Figure 5, TG, TC and non-HDL-C 
level were significantly increased from 88, 
170 and 93 mg/dl in NC rats to 154, 235 and 
196 mg/dl, respectively, in DC rats. After 28 
days of treatment, level of TG, TC and non-
HDL-C were significantly decreased in all 
the treated groups with a maximum decrease 
of 25 %, 38 % and 44 % observed in CT-1 
group, when compared to the corresponding 
DC values. The results demonstrated that 
feeding of plant extract PET-1 (50 mg/rat/ 
day), PET-2 (10 mg/rat/day) and glibencla-
mide was associated with a significant reduc-
tion in lipid parameters, however the reduc-
tion was less as compared to CT-1 group, 
which was more effective in reducting above 
lipid parameter, particularly TG levels. As 
seen in Figure 6, all the plasma lipoprotein 
lipids including atherogenic LDL-C were 
significantly increased in DC group, when 
compared to NC values. Our results showed 
that LDL-C, HDL-C and VLDL-C level 
were significantly increased from 76, 24 and 
18 mg/dl in NC to 165 (117 %), 40 (68 %) 
and 31 (76 %) mg/dl, respectively in DC 
rats. 
 
 
Table 4: Impact of P. virgatus methanolic extract, it´s partially purified fraction and glibenclamide on 
blood hemoglobin, its glycosylated form and plasma insulin in diabetic rats after 28 days of treatment 
GROUP Hemoglobin (g/dl) HbA1c (mg/dl) Insulin (ng/ml) 
NC* 14.80±0.09 4.25±0.79 6.01±1.25 
NC+PE* 14.78±0.22(-0.135%) a 5.75±0.84(+35.3 %) a 5.81±0.98(-3.3 %) a
DC** 9.14±0.17(-38.3  %) a 13.04±6.34(+206.8 %)a 2.85±1.01(-50.9 %) a
CT-1** 14.03±0.07(+53.5 %) a 4.45±0.36(-65.9 %)a 5.02±1.2(+76.1 %) a
CT-2** 13.76±0.14(+50.5 %) a 6.72±0.34(-48.5 %)a 4.15±0.88(+45.6 %) a
PET-1** 12.12±0.14(+32.6 %) a 4.49±0.25(-65.6 %)a 4.75±0.55(+66.7 %) a
PET-2** 11.31±0.22(+23.7 %) a 7.59±0.39(-41.8 %)a 3.56±0.61(+24.9 %) a
D-GT** 14.56 ± 0.45 (+59.3 %) a 5.33 ± 1.81 (-59.1 %) a 5.35 ± 1.1 (+83.5 %) a
 
* Values are mean  SD from 5 rats in N-C and NC+PE. 
** Values are mean  SD from 4 rats in D-C, CT-1, CT-2, PET-1, PET-2 and D-GT.Significantly different from N-C at 
a p < 0.001.Significantly different from D-C at ap < 0.001. 
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Figure 5: Effect of P. virgatus methanolic extract, its partially purified fraction and glibenclamide on 
plasma TG, TC and non-HDL-C level in diabetic rats after 28 days of treatment.  
Data are expressed as mean ± SD from 4 rats in each group except in NC and NC+PE that include 5 rats. ***a P < 0.01 signifi-
cantly different when compared with the corresponding value for normal control rats. ***b P < 0.001, significantly different when 
compared with the corresponding value for diabetic control 
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Figure 6: Effect of P. virgatus methanolic extract, its partially purified fraction and glibenclamide on 
plasma lipoproteins levels in diabetic-hyperlipidemic rats after 28 days of treatment.  
Data are expressed as mean ± SD from 4 rats in each group except in NC and NC+PE that include 5 rats. ***a P < 0.01 signifi-
cantly different when compared with the corresponding value for normal control rats. ***b P < 0.001, significantly different when 
compared with the corresponding value for diabetic control 
 
 
Treatment with P. virgatus methanolic ex-
tract, its partially isolated fraction and 
glibenclamide for 28 days showed a signifi-
cant reduction of 48 %, 43 %, 41 %, 32 % 
and 34 % in LDL-C level of CT-1,CT-2, 
PET-1, PET-2 and D-GT group, respectively 
when compared to corresponding values in 
DC groups. In comparison to DC group, the 
decline in HDL-C level was 8 %, 17 %, 1 % 
and 21 %, respectively, in CT-1, CT-2, PET-
1 and PET-2 group. The VLDL-C level of 
DC rats was also significantly increased 
from 18 mg/dl in NC to 31 mg/dl (76 %). All 
the five treated groups also exhibited a sig-
nificant reduction in VLDL-C level with a 
maximum reduction of 24 % observed in 
CT-1 groups. These results exemplify that 
decline in plasma lipid and lipoprotein level 
after 28 days of treatment with P. virgatus 
methanolic extracts and its partially purified 
fraction was due to significant decrease in 
LDL-C level.  
Since TC, LDL-C and HDL-C level were 
significantly increased in DC group and dif-
ferentially decreased following treatment of 
diabetic-hyperlipidemic rats with plant ex-
tract and its partially purified fraction. A 
consistent pattern was observed in all the ra-
tios, TC/HDL-C, HDL-C/LDL-C ratio was 
significantly increased by 20 % and 29 % in 
DC rats when compared to the control rats 
(Table 5). After treatment with plant extract 
and its partially purified fraction these ratios 
were significantly decreased in all the treated 
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Table 5: Impact of P. virgatus methanolic extract, it´s partially purified fraction and glibenclamide on 
the ratio of HDL-C/TC, HDL-C/LDL-C, TC/HDL-C and LDL-C/HDL-C in diabetic-hyperlipidemic rats af-
ter 28 days of treatment 
Group 
RATIOS† 
HDL-C/TC HDL-C/LDL-C TC/HDL-C  LDL-C/HDL-C 
NC* 0.201±0.010 0.318±0.047 4.95±0.010 3.21±0.047 
NC+PE* 0.189±0.017
 
(-5.8 %) c 
0.311±0.038 
(-2.2 %) c 
4.93±0.017 
(-0.4 %) c 
3.00±0.038 
(-6.5 %) c 
DC** 0.168±0.09 (-16.4 %) a 
0.241±0.006 
(-32.7 %) a 
5.922±0.09 
(+19.6 %) a 
4.14±0.006 
(+28.9 %) a 
CT-1** 0.251±0.0122 (+49.4 %) a 
0.426±0.0183 
(+76.8 %) a 
3.97±0.012 
(-32.9 %) a 
2.34±0.018 
(-43.5 %) a 
CT-2** 0.213±0.082 (+26.8 %) a 
0.354±0.019 
(+46.9 %) a 
4.61±0.082 
(-22.1 %) a 
2.81±0.019 
(-32.1 %) a 
PET-1** 0.243±0.005 (+44.6 %) a 
0.315±0.011 
(+30.7 %) a 
4.15±0.005 
(-29.9 %) a 
2.49±0.011 
(-39.9 %) a 
PET-2** 0.182±0.008 (+8.3 %) a 
0.279±0.027 
(+15.8 %) a 
5.50±0.008 
(-7.1 %)c 
3.58±0.027 
(-13.5 %) a 
D-GT** 0.210±0.005 (+25 %) a 
0.368±0.010 
(+52.7 %) a 
4.52±0.005 
(-23.6 %) a 
3.08±0.010 
(-25.6 %) a 
† For the calculation of ratios, data is taken from Figure 5 and 6. * Values are mean (mg/dl)  SD from 5 rats in N-C 
and NC+PE.**Values are mean (mg/dl)  SD from 4 rats in D-C, CT-1, CT-2, PET-1, PET-2 and D-GT. Significantly 
different from N-C at a p < 0.001. Significantly different from D-C at a p < 0.001 and c p>0.05. 
 
 
 
groups, with maximum reduction in CT-1 
groups. In addition, HDL/TC and HDL-
C/LDL-C ratios were significantly decreased 
in diabetic rats, which were significantly 
ameliorated after treatment with plant extract 
and its partially purified fraction. Here it is 
noteworthy to mention that these ratios 
which are predictor for cardiovascular dis-
ease risk were significantly and markedly re-
store after treatment of plant extract and par-
tially purified fraction with a marked restora-
tion in CT-1 group at a dose of 0.5 
mg/rat/day, when compared to other treated 
groups. 
 
DISCUSSION 
The rationale behind this work is based 
on our previously published data which illus-
trated that among the sequentially extracted 
various fraction of P. virgatus, methanolic 
extract showed the most potent antioxidant, 
genoprotective and α-amylase inhibitory ac-
tivity. Further, the extract showed enhanced 
glucose uptake in pre-adipose 3T3-L1 cell 
line and it was also non cytotoxic. The pre-
limnary GC-MS analysis of this extract re-
vealed several bioactive compounds and 
their inhibitory mechanism was validated via 
in silico analysis (Hashim et al., 2013). In 
the present study this methanolic extract was 
subjected to repetitive preparatory TLC in 
order to identify and isolate the partially pu-
rified fraction as well as to examine their 
role in STZ induced diabetes and diabetes 
linked hyperlipidemia in rats. Previous study 
also demonstrated the use of TLC mediated 
isolation of partially purified fraction for in 
vivo study (Gayathri et al., 2011). Our TLC 
data illustrated the presence of six prominent 
bands and the preliminary screening of these 
bands against α-amylase inhibitory activity 
showed that the 4th band has marked inhibi-
tory property (IC50 48 µg/ml), which depict-
ed that this fraction might be responsible for 
the antidiabetic activity of sequentially ex-
tracted methanolic fraction. Our initial 
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screening for the identification of bioactive 
compound in this fraction, via GC-MS anal-
ysis, showed the presence of benzoic acid, 
hexadecanoic acid, 9-octadecanoic acid and 
octadecanoic acid compounds, which are in 
agreement with the previously published re-
ports indicating the presence of these com-
pounds with antioxidant and antidiabetic 
properties (Kumar et al., 2010; Terpstra, 
2004). Among these compound hexadecano-
ic acid has already been known to play im-
portant role in biological process (Aleryani 
et al., 2005).  
STZ is known to induce diabetes in ani-
mal models along with hyperlipidem-
ia/atherosclerosis, diabetic nephropathy, ret-
inopathy, and neuropathy. STZ mediated 
toxicity is might be due to their proposed site 
of action at nuclear DNA. The decomposi-
tion of STZ leads to formation of highly re-
active carbonium ions, which cause DNA 
bases alkylation and also damage pancreatic 
-cell membrane and break the DNA strand 
which guide to the activation of poly (ADP-
ribose) synthetase and NAD depletion, 
which ultimately leads to cell death (Portha 
et al., 1989). It has been previously reported 
that STZ selectively destroy the pancreatic 
cells that secrete insulin and results in sub-
stantial hyperglycemia as well as also result 
in weight loss, ketosis and a high rate of 
mortality (Arulmozhi et al., 2004; Szku-
delski, 2001). Since, it has been shown that 
hyperglycemia is directly associated with 
decreased body weight of diabetic animals 
(Zafar and Naqvi, 2010), our data is in 
agreement with this study and also demon-
strated a decline in body weight in diabetic 
rats, that could be due to muscle destruction 
or degeneration of structural proteins (Sala-
huddin and Jalalpure, 2010). Repeated oral 
administration of methanolic extract and its 
partially isolated fraction showed gain in 
body weight. Among the treated group, CT-1 
group showed maximum gain in body weight 
followed by CT-2 > PET-1 > PET-2 groups 
which may be due to the reversal of hepatic 
gluconeogenesis accompanied with the sup-
pression of lipolysis of adipose tissue (Rob-
ertson, 2007; Postic et al., 2001). 
The present data revealed that fasting 
plasma glucose level was significantly in-
creased and insulin level was decreased in 
STZ induced diabetic rats in comparison to 
rats in NC group. Among all the treatment 
groups, the partially isolated fraction (CT-1 
group) of plant extract at a dose of 0.5 mg/ 
rats/day for 28 days showed a significant de-
crease in the plasma glucose level and in-
crease in insulin level. The plant extract and 
partially purified fraction being a potent free 
radical scavenger and inhibitor of lipid pe-
roxidation (Hashim et al., 2013), might pre-
vents STZ-induced oxidative stress and pro-
tects or regenerate insulin producing -cells 
resulting in increased insulin secretion and 
decreased blood glucose levels. At present, 
the finding of this study is in agreement with 
previously published data which illustrated 
the antioxidant and antihyperglycemic effect 
of Phyllanthus simplex crude methanol ex-
tract (Shabeer et al., 2009). 
The extent of hemoglobin glycation is 
currently used as a cumulative index of gly-
cemia over the previous few weeks in the 
clinical management of diabetes (Saudek and 
Rastogi, 2004). In diabetes, there is a for-
mation of advanced glycation end products 
when glucose interact with various proteins 
such as hemoglobin, albumin, collagen, 
LDL, or crystalline proteins to form labile 
Schiff bases, which further undergoes modi-
fication to form Amadori products (Klein, 
1995; Singh et al., 2001; Ahmad et al., 
2013). Evidence showed that glycation itself 
may induce the formation of oxygen-derived 
free radicals in diabetic condition, and the 
level of HbA1c is considered as one of the 
markers of degree of oxidative stress in dia-
betes mellitus (Bravi et al., 2006). Therefore, 
the measurement of HbA1c is supposed to be 
a very sensitive index for glycemic control 
(Norris, 2002). Our results demonstrated a 
substantial decrease in hemoglobin and a 
significant increase in HbA1c levels in dia-
betic rats, which is in agreement with earlier 
finding (Nathan et al., 2007). In the present 
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investigation, rats in DC group showed high-
er levels of HbA1c, compared with those of 
control group. After 28 days of treatment 
with P. virgatus methanolic extract and its 
partially isolated fraction, both Hb and 
HbA1c levels were significantly ameliorated 
close to normal control values with a marked 
restoration in CT-1group (54 & 66 %), 
which could be due to an improvement in 
hyperglycemia. Present findings bear a re-
semblance with previously published data 
that showed the treatment of Phyllantus sel-
lowianus (Hnatyszyn et al., 1997) and Phyl-
lanthus emblica ethanolic (Krishnaveni et 
al., 2010) extracts to STZ induce diabetic 
rats significantly ameliorated blood glucose 
and HbA1c level. 
Since, diabetes mellitus is related with 
increased propensity to accelerated athero-
genesis, and is directly correlated with ab-
normalities in lipid profile, which are one of 
the major contributing causes of micro and 
macrovascular complications in diabetic pa-
tients (Ono et al., 1998; Giugliano et al., 
1996). Oxidative stress also plays an im-
portant role in diabetes that results in in-
creased glycation and increased oxidation of 
lipoprotein (Bowie et al., 1993), particularly 
LDL, which could be one of the mechanisms 
for an early development of atherosclerosis 
in diabetes. Thus, it is worthwhile to evalu-
ate the role of this plant and their bioactive 
fraction in the prevention of hyperlipidemia, 
which is directly related with STZ-induced 
diabetes in rats. As expected, our data 
showed a marked increase in TG, TC, and 
non-HLD-C levels in diabetic-hyperlipidem-
ic rats when compared to normal control rats.  
The observed increase in cholesterol lev-
el of diabetes was may be due to increase in 
3-hydroxy-3-methylglutaryl coenzyme-A 
(HMG-CoA) reductase activity and is in 
concordant with several reports that showed 
increase HMG-CoA reductase activity in di-
abetic rats (Prince and Kannan, 2006; 
Rydgren and Sandler, 2009). This increase in 
cholesterol level has been shown to be asso-
ciated with the deficiency in insulin which 
can be due to enhanced mobilization of lipid 
from adipose tissue to plasma (Karthikesan 
et al., 2010). 
After 28 days of treatment with plant ex-
tract and partially purified fraction at differ-
ent doses, a significant reduction was ob-
served in TG, TC and non-HDL-C level. 
Similarly, VLDL-C, LDL-C and HDL-C 
levels were significantly increased in diabet-
ic rats, which were significantly reduced af-
ter treatment with plant extract, partially pu-
rified compound or glibenclamide. Our data 
showing an increase in plasma HDL-C level 
in DC group is consistent with other reports, 
where a significant increase in HDL-C level 
in diabetic rats has been reported (Ebara et 
al., 1994; Kobayshi et al., 2000). Further, 
glibenclamide treated group also depicted 
reduction in plasma lipid and lipoprotein 
level and is consistent with earlier findings 
(Ratzmann et al.,1983; Tamai et al., 1981), 
but the reduction was much less as compared 
to CT-1 & CT-2 group. Moreover glibencla-
mide is associated with severe side effects 
like mental status, seizure, coma and death 
(Burge et al., 1998; Asplund et al., 1983; 
Sills et al.,1997). 
It has been established that LDL-C/HDL-
C and HDL-C/TC ratios are good predictors 
for the presence and severity of CAD 
(Drexel et al., 1992). In addition to LDL-
C/HDL-C and HDL-C/TC ratios, we have 
also presented the ratios of HDL-C/LDL-C 
and TC/HDL-C, which were markedly in-
creased in D-C rats, respectively, in compar-
ison to the corresponding ratios in N-C rats, 
as well as these data are in resemblance with 
previous reports (Heidarian and Soofiniya, 
2011). Treatment with plant extract and par-
tially purified fraction resulted in a signifi-
cant improvement in these ratios, indicating 
normalization of above lipid and lipoprotein 
lipid parameters. The hypolipidemic activity 
of plant extract and partially purified fraction 
might be attributed to the decrease in HMG-
CoA reductase activity which could be due 
to an increase in insulin activity along with 
an associated amelioration of both glucose 
and lipid levels. There are several in vitro 
and in vivo reports which indicated that re-
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duction in the enzymatic activity of HMG-
CoA reductase by plant extract is directly as-
sociated with decrease in plasma lipid and 
lipoprotein levels (Iqbal et al., 2014a, b; 
Khan et al., 2011). Here, it is interesting to 
mention that same fraction (CT-1) which il-
lustrated most potent hypoglycemic activity, 
also showed remarkable hypolipidemic 
property in vivo. These finding are in con-
cordant with previously published data 
which illustrated the hypolipidemic activity 
of various species of phyllanthus in STZ in-
duced diabetic rats (Okoli et al., 2010; 
Mbagwu et al., 2011).Thus, in addition to 
glycaemic control, extract of this plant may 
further reduce mortality from complications 
of the disease by ameliorating diabetes-indu-
ced hyperlipidemia. This profound activity 
of CT-1 and CT-2 group might be attributed 
to the synergistic effect of bioactive com-
pounds viz. hexadecanoic acid and octadeca-
noic acid compound, present in this fraction. 
 
CONCLUSION 
From the data presented above, it has 
been extracted that methanolic extract of this 
plant and their partially purified fraction ex-
ert potent hypoglycemic and hypolipidemic 
activity. Moreover, the methanolic extract at 
higher dose (50 mg/rat/day) gave good re-
sponse, while the partially purified fraction 
at a dose comparable to standard (0.5 mg/ 
rat/day and 0.1 mg/rat/day ) illustrated im-
proved hypoglycemic and hypolipidemic ac-
tivity than the glibenclamide treated diabetic 
rats. Further, purification of this fraction and 
specific structure elucidation is necessary for 
development of hypoglycemic and hypoli-
pidemic drug. The combined results has un-
doubtedly provided scientific confirmation 
and evidence for the use of P. virgatus meth-
anolic extract and its partially purified frac-
tion and demonstrate that strong hypoglyce-
mic, hypolipidemic and antidiabetic impacts 
of this plant coupled with their potent antiox-
idative property, can provide additional ben-
efits in the inhibition of oxidative stress and 
hence in the prevention and treatment of dia-
betes linked hyperlipidemia. 
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